OIP Approval summaries

Every approval, one line for patients.

What EMA, FDA and HAS decided, act by act, each line written from the agency's own words and checked against them.

EMAKeytruda2018-08-27

The agency's words

Keytruda, in combination with pemetrexedand platinum chemotherapy, is indicated for thefirst-line treatment of metastatic non-squamous NSCLC

Moved earlier

Now a first-line option with chemotherapy for metastatic non-squamous lung cancer

Checked against the source

TEKKARE®
Inspired by Healthcare

OIP Approval summaries

Sign in

Use your OIP account to read what changed in each drug's approvals.

No password to remember. We'll email you a single-use 6-digit code.

or

Access comes with your OIP licence. Ask your Tekkare contact if you need one.